Fmr LLC Acquires 4,996 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Fmr LLC boosted its holdings in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 25.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 24,721 shares of the biotechnology company’s stock after purchasing an additional 4,996 shares during the period. Fmr LLC owned about 0.17% of Anika Therapeutics worth $611,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Eastern Bank acquired a new position in Anika Therapeutics during the third quarter worth $28,000. Quest Partners LLC boosted its position in Anika Therapeutics by 115.8% in the third quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after buying an additional 3,705 shares in the last quarter. Atria Investments Inc acquired a new position in Anika Therapeutics in the third quarter valued at about $218,000. SG Americas Securities LLC boosted its holdings in shares of Anika Therapeutics by 43.1% in the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 2,858 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. bought a new position in Anika Therapeutics in the 3rd quarter valued at $238,000. 91.53% of the stock is currently owned by institutional investors.

Anika Therapeutics Stock Down 3.5 %

Shares of ANIK stock opened at $16.04 on Thursday. The firm has a market cap of $234.92 million, a price-to-earnings ratio of -2.41 and a beta of 0.89. Anika Therapeutics, Inc. has a 12 month low of $15.82 and a 12 month high of $29.11. The stock has a 50-day moving average price of $19.50 and a 200 day moving average price of $23.63.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ANIK. Barrington Research cut their price target on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a report on Friday, November 1st. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.